The peptidic urotensin‐II receptor ligand GSK248451 possesses less intrinsic activity than the low‐efficacy partial agonists SB‐710411 and urantide in native mammalian tissues and recombinant cell systems

David J. Behm(GlaxoSmithKline (United States)), Stephen A. Douglas(GlaxoSmithKline (United States)), Valeria Camarda(University of Ferrara), James A. Fornwald(GlaxoSmithKline (United Kingdom)), Nambi Aiyar(New Frontier), Girolamo Calò(University of Padua), James J. Foley(GlaxoSmithKline (United Kingdom)), Henry M. Sarau(GlaxoSmithKline (United Kingdom)), Robert S. Ames(GlaxoSmithKline (United Kingdom)), Gerald P. Stankus(GlaxoSmithKline (United Kingdom)), Christopher Doe(GlaxoSmithKline (United Kingdom)), Dulcie B. Schmidt(GlaxoSmithKline (United Kingdom)), Robert N. Willette(New Frontier), David G. Lambert(University of Leicester), Parvathi Nuthulaganti(GlaxoSmithKline (United Kingdom))
British Journal of Pharmacology
March 20, 2006
10.1038/sj.bjp.0706716
Cited by 36

Related Papers

THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors
|British Journal of Pharmacology|2021|488
Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic
|Nature|2012|474
Pharmacology of nociceptin and its receptor: a novel therapeutic target
|British Journal of Pharmacology|2000|432
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors
|British Journal of Pharmacology|2023|390
Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems
|Pharmacological Reviews|2016|290